Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Research and Innovation Action · Running

NEMESIS Novel Effect biomarkers for MEtabolic disruptorS: evidence on health Impacts to answer science and policy needS

Coordinator
Ita-Suomen Yliopisto, Finland
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€7.9m
Total cost
€8.0m
Partners
15 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101137405

What the project is doing

In the project's own words, from its summary on CORDIS.

Endocrine-disrupting chemicals (EDCs) disturb lipid and glucose metabolism in several metabolically active organs such as liver and pancreas besides being able to interfere with many aspects of hormonal action. There is accumulating evidence linking EDCs or their mixtures with an increased incidence of obesity, atherosclerosis, and type 2 diabetes. Developmental exposure to EDCs can exert life-long, even transgenerational effects and affects the susceptibility to many diseases.

However, the metabolic effects of EDCs are still poorly understood and the lack of mechanistic data and predictive models of adverse metabolic outcomes of EDCs hinders their risk assessment. The “Novel Effect biomarkers for MEtabolic disruptorS: evidence on health Impacts to science and policy needS” (NEMESIS) consortium brings together experts in toxicology, medicine, risk assessment, and social sciences and humanities to respond to the unmet regulatory needs of EDCs within silico, in vitro, in vivo, epidemiological and systems biology data on EDC-mediated metabolic effects in multifactorial models.

We will assess mechanistic data on metabolic disruption in liver and pancreas and how EDCs or their mixtures affect the microbiota, enhanced with data on dose-response relationships and the causality of these actions. In addition, NEMESIS will provide human exposure data of EDCs and explore effect biomarkers for metabolic disruption. NEMESIS’ results will improve assessment of metabolic endpoints in testing guidelines and adopt alternative models to animal testing.

Adverse Outcome Pathways (AOP)s and Integrated Approaches to Testing and Assessment (IATA) approaches will be developed to assess adverse metabolic effects of EDCs and improve the risk assessment towards a more holistic approach. Citizens are engaged from the beginning of the project to develop effective risk communication practices on EDCs and to maximize the science-to-policy impact of NEMESIS together with relevant stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Ita-Suomen YliopistoKuopioFinlandCoordinator
Universite Libre De BruxellesBruxellesBelgiumParticipant
Universiteit HasseltHasseltBelgiumParticipant
Novamechanics LimitedNicosiaCyprusParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Robert Bosch Gesellschaft Fur Medizinische Forschung MbhStuttgartGermanyParticipant
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceParticipant
Novamechanics Monoprosopi IkePiraeusGreeceThird party
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Fundacion Para La Investigacion Y La Innovacion Biosanitaria Del Principado De AsturiasOviedoSpainParticipant
Oulun YliopistoOuluFinlandParticipant
Tampereen Korkeakoulusaatio SrTampereFinlandParticipant
Universidade Nova De LisboaLisboaPortugalParticipant
Karolinska InstitutetStockholmSwedenParticipant
Umea UniversitetUmeaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI